JAK Inhibitors as a Novel Approach to Autoimmune Bullous Diseases: A Review
Dermatologic Therapy, Volume 2026, Issue 1, 2026.Autoimmune bullous diseases (AIBDs) are a group of chronic disorders characterized by blister formation resulting from abnormal immune responses. Janus kinase (JAK) inhibitors have emerged as promising therapeutic agents for AIBDs. This review discusses the use of JAK inhibitors—such as upadacitinib, baricitinib, tofacitinib, and abrocitinib, among ...
Olga Olisova +9 more
wiley +1 more source
Dermatologic Therapy, Volume 2026, Issue 1, 2026.Background Direct evidence comparing single‐agent and combination regimens for vitiligo is limited and often overlooks longitudinal outcomes. This study evaluated how combination therapy versus monotherapy influenced repigmentation, measured by the Vitiligo Area Scoring Index (VASI), in a real‐world clinical setting.
Amr Molla +2 more
wiley +1 more source
Urginea indica and its role in psoriasis: A Review [PDF]
, 2012 Psoriasis an inflammatory disease of the skin, non-infections. It is an increased proliferation of the skin layers due to excessive division of the cell in the basal layers of the skin.
Paramasivam, G., Shiva Kameshwari, M.N.
core
JEADV Clinical Practice, Volume 4, Issue 5, Page 1207-1209, December 2025.ABSTRACT Alopecia areata (AA) and bullous pemphigoid (BP) are distinct autoimmune diseases, but growing evidence points to overlapping immune pathways. We present a rare case of a 71‐year‐old woman with concurrent AA and BP. She initially presented with 10 months of progressive scalp and body hair loss (Severity of Alopecia Tool [SALT] ~ 80) and nail ...
Anna Brinks +6 more
wiley +1 more source
275 Effects of ruxolitinib cream on sleep and quality of life over 52 weeks in black patients with atopic dermatitis [PDF]
, 2022 Atopic dermatitis (AD) is an inflammatory skin disease with phenotypic differences across race and can affect sleep and quality of life (QoL).
Brar, K. K +8 more
core +1 more source
43938 Total Vitiligo Area Scoring Index Response Maintenance or Shift During 52 Weeks of Ruxolitinib Cream Treatment for Vitiligo: Pooled Analysis of the TRuE-V Phase 3 Studies [PDF]
, 2023 David Rosmarin +9 more
openalex +1 more source
Janus kinase inhibitors may be an effective treatment to reduce skin depigmentation in vitiligo [PDF]
, 2020 A clinical decision report appraising Rothstein B, Joshipura D, Saraiya A, Abdat R, Ashkar H, Turkowski Y, Sheth V, Huang V, Au SC, Kachuk C, Dumont N, Gottlieb AB, Rosmarin D. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib.
Lohman, Shannon E
core +1 more source
Itch and Janus Kinase Inhibitors [PDF]
, 2023 Itch is a common skin symptom, with complex aetiology and pathogenesis. It is mediated by 2 pathways, the histaminergic and non-histaminergic pathways.
Cho, Sang Hyun +4 more
core +1 more source
1264 Ruxolitinib cream inhibits depigmentation in an adoptive transfer mouse model of vitiligo [PDF]
, 2023 M. Parker +3 more
openalex +1 more source
Comparative Efficacy of Monotherapies for Chronic Hand Eczema: A Network Meta‐Analysis Study
Journal of Cosmetic Dermatology, Volume 24, Issue 12, December 2025.ABSTRACT Introduction Chronic hand eczema (CHE) is a highly prevalent dermatology‐related occupational hazard. This condition, which is a distinct diagnosis from atopic dermatitis (AD), can be quite symptomatic with implications for one's personal and professional life.
Aditya K. Gupta +2 more
wiley +1 more source